Prolynx is a biotechnology company dedicated to developing ultra-long-acting medicines for obesity and other metabolic diseases. The Company is advancing a proprietary portfolio of extended-duration therapeutic candidates, targeting once monthly and once-quarterly dosing, optimized to smooth the peaks and troughs that can contribute to tolerability issues, and to support more consistent, long-term treatment.
Leadership & Board
Current Number of Employees39
Current LinkedIn Followers3,018
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$70M
Total Amount Raised$70M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$70M
Latest Funding Amount$70M
Latest Funding RoundSeries A
Latest Funding RoundSeries A
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
Prolynx had 39 employees as of September 14, 2026. The number of employees increased by 0 (0.00%) week-over-week.
39Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
Prolynx had 3,018 followers as of September 14, 2026. The number of followers increased by 3 (0.10%) week-over-week.
3,018Latest Followers Count
3(0.10%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.